MAPT and Parkinson disease: In parallel, tau-lowering with intrathecal ASOs (e.g., BIIB080) has reduced CSF tau and tau-PET in humans, providing a translatable platform for PD trials enriched for tau co-pathology (e.g., MAPT H1/H1 carriers, elevated plasma pTau217) (NCT05399888).